-
1 Comment
TherapeuticsMD, Inc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.9.
TherapeuticsMD, Inc's total revenue rose by 42.0% to $23M since the same quarter in the previous year.
Its net income has increased by 14.9% to $-42M since the same quarter in the previous year.
Finally, its free cash flow grew by 56.9% to $-31M since the same quarter in the previous year.
Based on the above factors, TherapeuticsMD, Inc gets an overall score of 4/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | US88338N1072 |
| Market Cap | 13M |
|---|---|
| PE Ratio | None |
| Target Price | 5 |
| Beta | 0.95 |
| Dividend Yield | None |
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TXMD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
